Clinical laboratory evaluations of aprepitant for the treatment of opioid depende

阿瑞吡坦治疗阿片类药物依赖的临床实验室评价

• 批准号: 7886851
• 负责人: Stephen Ross
• 金额: $ 36.94万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2013-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7886851
• 关键词: Acute; Attenuated; Behavioral; Behavioral Model; Characteristics; Choice Behavior; Clinical; Cues; Drug Metabolic Detoxication; Evaluation; Genetic Polymorphism; Heroin; Laboratories; Modeling; Morphine; Naloxone; Opiate Addiction; Opioid; Patients; Pharmaceutical Preparations; Pharmacogenetics; Psychological reinforcement; Receptor Gene; Rewards; Stress; Testing; Therapeutic; Withdrawal; aprepitant; base; behavior test; craving; disorder later incidence prevention; drug craving; experience; mu opioid receptors; opioid withdrawal; preclinical study; psychologic; public health relevance; receptor; response

DESCRIPTION (provided by applicant): Current treatments for opioid dependence would benefit by the addition of a non-opioid based treatment medication. Recent pre-clinical studies have demonstrated the involvement of the NK1 rector in opioid reward and withdrawal. This study proposes to investigate a clinically available NK1 antagonist, aprepitant, in opioid dependent patients. Based on the unique behavioral and pharmacological characteristics of opioid addiction, and what is known of the currently employed treatments, we propose that the therapeutic mechanism of any potential opioid addiction treatment medication must include the ability to reduce opioid withdrawal. This is of particular importance during treatment initiation (e.g., detoxification). In addition, for long-term treatment and relapse prevention it is important to manage drug craving, to ameliorate the effects of stress, and inhibit the rewarding effects of opioids if patients do experience a slip. Therefore, we propose to study aprepitant in the clinical laboratory, using models of acute opioid reward, reinforcement and withdrawal, as well as stress- and cue-exposure responding. PUBLIC HEALTH RELEVANCE: This study proposes to investigate a clinically available NK1 antagonist, aprepitant, in opioid dependent patients. Aprepitant will be tested in the clinical laboratory, using models of acute opioid reward, reinforcement and withdrawal, as well as stress- and cue-exposure responding.

描述（由申请人提供）：目前对阿片类药物依赖的治疗将受益于添加非阿片类药物的治疗药物。最近的临床前研究表明 NK1 受体参与阿片类药物的奖励和戒断。本研究旨在研究一种临床可用的 NK1 拮抗剂阿瑞匹坦用于阿片类药物依赖患者的治疗。基于阿片类药物成瘾的独特行为和药理学特征，以及目前所采用的治疗方法，我们建议任何潜在的阿片类药物成瘾治疗药物的治疗机制必须包括减少阿片类药物戒断的能力。这在治疗开始（例如戒毒）期间尤为重要。此外，对于长期治疗和预防复发来说，控制药物渴望、减轻压力的影响以及在患者确实出现滑倒时抑制阿片类药物的奖励作用也很重要。因此，我们建议在临床实验室中使用急性阿片类药物奖励、强化和戒断以及压力和线索暴露反应模型来研究阿瑞吡坦。 公共健康相关性：本研究旨在研究一种临床可用的 NK1 拮抗剂阿瑞匹坦用于阿片类药物依赖患者的疗效。阿瑞吡坦将在临床实验室使用急性阿片类药物奖赏、强化和戒断以及压力和线索暴露反应模型进行测试。